Diagnosis and Risk Stratification of Plasma Cell Disorders (pt 1 of 5 - IMF ASH Satellite)

Diagnosis and Risk Stratification of Plasma Cell Disorders (pt 1 of 5 - IMF ASH Satellite)

Upfront Therapy for the ASCT-Eligible Patient: (pt. 3 of 5 - IMF ASH Satellite)Подробнее

Upfront Therapy for the ASCT-Eligible Patient: (pt. 3 of 5 - IMF ASH Satellite)

2020 Treatment Algorithm for Multiple Myeloma and Conclusions (part 5 of 5 - IMF ASH 2019 Satellite)Подробнее

2020 Treatment Algorithm for Multiple Myeloma and Conclusions (part 5 of 5 - IMF ASH 2019 Satellite)

Risk Stratification of Plasma Cell DisordersПодробнее

Risk Stratification of Plasma Cell Disorders

Plasma Cell DisordersПодробнее

Plasma Cell Disorders

Treatment and Survival of Patients with Primary Plasma Cell LeukemiaПодробнее

Treatment and Survival of Patients with Primary Plasma Cell Leukemia

Plasma cell disordersПодробнее

Plasma cell disorders

Plasma Cell Proliferative Disorders: Use of the Laboratory for Diagnosis and PrognosticationПодробнее

Plasma Cell Proliferative Disorders: Use of the Laboratory for Diagnosis and Prognostication

New Standard of Care for High-Risk Smoldering Multiple Myeloma: Insights from ASH 2024Подробнее

New Standard of Care for High-Risk Smoldering Multiple Myeloma: Insights from ASH 2024

Identification of myeloma high-risk subclones with single-cell technologiesПодробнее

Identification of myeloma high-risk subclones with single-cell technologies

Plasma Cell Dyscrasias and The Kidney diagnosis Dr Mohammed Abdel GawadПодробнее

Plasma Cell Dyscrasias and The Kidney diagnosis Dr Mohammed Abdel Gawad

MCRT Phoenix 2017: MM Diagnosis and Risk Stratification by Shaji Kumar, MDПодробнее

MCRT Phoenix 2017: MM Diagnosis and Risk Stratification by Shaji Kumar, MD

Update on diagnosis and therapy of plasma cell dyscrasiasПодробнее

Update on diagnosis and therapy of plasma cell dyscrasias

Plasma Cell NeoplasmsПодробнее

Plasma Cell Neoplasms

Evolution of Upfront Therapy for the ASCT-Ineligible Patient (pt 2 of 5 - IMF ASH 2019 Satellite)Подробнее

Evolution of Upfront Therapy for the ASCT-Ineligible Patient (pt 2 of 5 - IMF ASH 2019 Satellite)

Treatments for Early Stage Plasma Cell DisordersПодробнее

Treatments for Early Stage Plasma Cell Disorders

What is mSMART? What is risk stratification? #myelomaПодробнее

What is mSMART? What is risk stratification? #myeloma

Risk Stratification for MyelomaПодробнее

Risk Stratification for Myeloma

International Myeloma Foundation Virtual Regional Community Workshop (RCW) - Eastern MidwestПодробнее

International Myeloma Foundation Virtual Regional Community Workshop (RCW) - Eastern Midwest

Новости